The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease

(2019) Klaus Romero et al.   CTS-Clinical and Translational Science

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials

(2018) Jesse M. Cedarbaum   MOVEMENT DISORDERS

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

(2018) S. Pablo Sardi et al.   MOVEMENT DISORDERS

Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations

(2018) Anthony E. Lang et al.   MOVEMENT DISORDERS

Finding useful biomarkers for Parkinson’s disease

(2018) Alice S. Chen-Plotkin et al.   Science Translational Medicine

The burden of Parkinson's disease: a worldwide perspective

(2018) Walter A Rocca   LANCET NEUROLOGY

Importance of low diagnostic Accuracy for early Parkinson's disease

(2018) Thomas G. Beach et al.   MOVEMENT DISORDERS

123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease

(2018) Christos Koros et al.   MOVEMENT DISORDERS

A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein

(2018) Kalpana M. Merchant et al.   Journal of Parkinsons Disease

The Emerging Evidence of the Parkinson Pandemic

(2018) E. Ray Dorsey et al.   Journal of Parkinsons Disease

Challenges and unfulfilled promises in Parkinson's disease

(2017) A Jon Stoessl   LANCET NEUROLOGY

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials

(2017) Alberto J. Espay et al.   MOVEMENT DISORDERS

New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States

(2017) Karl Kieburtz et al.   MOVEMENT DISORDERS

Zeroing in on neurodegenerative α-synuclein

(2017) Katie Kingwell   NATURE REVIEWS DRUG DISCOVERY

What evidence do we need for biomarker qualification?

(2017) Chris Leptak et al.   Science Translational Medicine

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort

(2017) Danna Jennings et al.   JAMA Neurology

Molecular imaging of dopamine transporters

(2016) David J. Brooks   AGEING RESEARCH REVIEWS

Therapeutic approaches in Parkinson's disease and related disorders

(2016) Elvira Valera et al.   JOURNAL OF NEUROCHEMISTRY

Accuracy of clinical diagnosis of Parkinson disease

(2016) Giovanni Rizzo et al.   NEUROLOGY

Autosomal dominant Parkinson's disease caused by SNCA duplications

(2016) Takuya Konno et al.   PARKINSONISM & RELATED DISORDERS

Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization

(2015) S Amur et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CNS biomarkers: Potential from a regulatory perspective

(2015) Maria Isaac et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies

(2015) Roberto Erro et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

The European Medicines Agency's strategies to meet the challenges of Alzheimer disease

(2015) Manuel Haas et al.   NATURE REVIEWS DRUG DISCOVERY

Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family

(2015) Simone Olgiati et al.   PARKINSONISM & RELATED DISORDERS

Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease 1

(2015) Diane Stephenson et al.   Journal of Parkinsons Disease

Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?

(2014) Amy Reeve et al.   AGEING RESEARCH REVIEWS

Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease

(2014) Derek L.G. Hill et al.   Alzheimers & Dementia

Glucocerebrosidase is shaking up the synucleinopathies

(2014) Marina Siebert et al.   BRAIN

Molecular Imaging Insights into Neurodegeneration: Focus on  -Synuclein Radiotracers

(2014) M. Shah et al.   JOURNAL OF NUCLEAR MEDICINE

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

(2014) K. Marek et al.   NEUROLOGY

Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study

(2014) C. H. Adler et al.   NEUROLOGY

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes

(2013) Nin Bajaj et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease

(2012) Bernard Ravina et al.   MOVEMENT DISORDERS

SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0

(2011) D. S. W. Djang et al.   JOURNAL OF NUCLEAR MEDICINE

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

Imaging biomarkers in Parkinson's disease

(2011) David J. Brooks et al.   PROGRESS IN NEUROBIOLOGY

The Role of the Core Imaging Laboratory in Multicenter Trials

(2010) John Seibyl et al.   SEMINARS IN NUCLEAR MEDICINE

EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

(2009) Jacques Darcourt et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING